RxDoctor Payments Data

Cassandra Burt-Ernst, PA

Physician Assistant · Jacksonville, FLNPI 1285767103

Payments from drug & device makers

$6,792in general payments, 2019–2025

Across 280 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$1K
  • Novo Nordisk$729
  • Abbott$705
  • Amgen$500
  • Bayer$394
  • Boehringer Ingelheim$385
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$6,792100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,792 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$179,528
Medicare patients
635
Services billed
2,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$140,028
JardianceEmpagliflozin54$58,331
Humulin R U-500Insulin Regular, Human22$40,513
TrulicityDulaglutide28$31,311
FarxigaDapagliflozin Propanediol25$29,642
JanuviaSitagliptin Phosphate21$26,616
Tresiba Flextouch U-100Insulin Degludec31$23,792
Tresiba Flextouch U-200Insulin Degludec26$19,403
Novolog FlexpenInsulin Aspart43$15,008
MounjaroTirzepatide11$13,462
Lantus SolostarInsulin Glargine,hum.Rec.Anlog77$11,252
Humalog Kwikpen U-100Insulin Lispro13$4,467
Nano 2nd Gen Pen NeedlePen Needle, Diabetic23$3,654
SynthroidLevothyroxine Sodium40$2,964
Levothyroxine Sodium271$2,284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$729$140,02898 claims
Boehringer IngelheimJardiance$385$58,33154 claims
Lilly USA, LLCTrulicity, Mounjaro$334$44,77339 claims
AstraZenecaFarxiga$237$29,64225 claims
MerckJanuvia$34$26,61621 claims
AbbVieSynthroid$28$2,96440 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$232$2,284271 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →